ZNTL Stock Recent News

Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously disclosed, the Company aligned with the U.S. Food and Drug Administration (FDA) on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial: Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company's common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 50,000 shares of the Company's common stock and 25,000 restricted stock units to one newly hired employee. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG

NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / NEW YORK, February 27, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.